9 Results for "

β-arrestin inhibition

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "β-arrestin inhibition" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-120645
CAS No.: 313669-88-4
Purity:  99.90%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ 35S]GTPγS binding in mouse brain membranes .
loading...
    loading...
Cat. No.: HY-175818
Target:  

Apelin Receptor (APJ)

Research Areas:  

Cancer

APJ antagonist-1 is an apelin receptor (APJ) antagonist. APJ antagonist-1 shows strong β-arrestin inhibition with an IC50 of 3.1 μM. APJ antagonist-1 selectively inhibits APJ-overexpressing cancer cells and suppresses apelin-induced endothelial cell migration. APJ antagonist-1exhibits high metabolic stability. APJ antagonist-1 can used for the studies of ovarian cancer and tumor angiogenesis .
loading...
    loading...
Cat. No.: HY-175984
Target:  

LPL Receptor

Research Areas:  

Inflammation/Immunology

S1P1 agonist 7 is a potent, orally active, and β-arrestin-biased S1P1 agonist (EC50(G‑protein) = 12.7 nM and EC50(β‑arrestin) = 3.23 nM). S1P1 agonist 7 demonstrates potent immunomodulatory activity and a favorable safety profile. S1P1 agonist 7 exhibits excellent metabolic stability, minimal to moderate CYP inhibition, and S1P3-sparing selectivity. S1P1 agonist 7 shows pharmacokinetics, effectively reduces circulating lymphocytes, and significantly alleviates disease severity in experimental autoimmune encephalomyelitis (EAE) mouse models under both prophylactic and therapeutic regimens. S1P1 agonist 7 can be used for multiple sclerosis (MS) research .
loading...
    loading...
Cat. No.: HY-123534
CAS No.: 213769-33-6
Purity:  99.74%
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CYT-1010 is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC50s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively .
loading...
    loading...
Cat. No.: HY-123534A
CAS No.: 1161517-81-2
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

CYT-1010 hydrochloride is a mu-opioid receptor agonist extracted from patent WO2013173730A2, with EC50s of 13.1 nM and 0.0053 nM on beta-arrestin recruitment and inhibition of cAMP production, respectively .
loading...
    loading...
Cat. No.: HY-150056
CAS No.: 2633686-36-7
Purity:  98.05%
Research Areas:  

Neurological Disease

CB1R Allosteric modulator 3 is a CB1R positive allosteric modulator. CB1R Allosteric modulator 3 has potent inhibition of cAMP and β-Arrestin with EC50 values of 0.018 μM and 1.241 μM, respectively .
loading...
    loading...
Cat. No.: HY-171069
CAS No.: 1312799-06-6
Research Areas:  

Metabolic Disease

FFA2 agonist-1 (Compound 4) is the agonist for Free fatty acid receptor 2 (FFA2/GPR43) with an EC50 of 81 nM. FFA2 agonist-1 exhibits activity in β-arrestin-2 recruitment assay and cAMP inhibition assay with EC50 of 1.2 μM and 0.53 μM. FFA2 agonist-1 leads to appetite regulating peptide YY (PYY) mucosal responses, inhibits the fat accumulation, intestinal functions and food intake, and can be used for obesity research .
loading...
    loading...
Cat. No.: HY-157425
CAS No.: 1216074-15-5
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

5-HT2CR agonist 1 (compound 8), a 7-chloro analogue, is a selective 5-HT2CR partial agonist (Emax=71.09%) with an EC50 value of 121.5 nM and no observed activity toward 5-HT2AR or 5-HT2BR. 5-HT2CR agonist 1 exhibits no recruitment activity for β-arrestin and shows low inhibition of hERG at 10 μM .
loading...
    loading...
Cat. No.: HY-184490
CAS No.: 3118558-91-8
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

BPR1M492 is a brain-penetrant μ-opioid receptor (MOR) agonist an in vitro EC50 of 0.93 nM in the cAMP inhibition assay and 0.004 nM in the FLIPR Ca 2+ assay without a clear signaling bias between cAMP and β-arrestin-2 pathway. BPR1M492 is a cAMP-biased nociceptin-orphanin FQ opioid peptide agonist. BPR1M492 is a weak cAMP-biased δ/κ-opioid receptor agonist. BPR1M492 demonstrates potent in vivo antinociception and can be used for pain research .
loading...
    loading...